Protagonist Therapeutics Earned $10M Milestone Payment From Johnson & Johnson Following The Dosing Of The Third Patient In Phase 2b ANTHEM-UC Trial Of JNJ-2113 Compared With Placebo For Moderate To Severe Active Ulcerative Colitis
Author: Benzinga Newsdesk | December 13, 2023 08:42am